Lisa Roberts-Rapp

1.0k citations

36 papers · 634 indexed · h-index 12

Molecular Biology
Oncology top 10%
Genetics top 5%
Radiology, Nuclear Medicine and Imaging top 10%
Hematology top 10%

Co-authors: Peter Ansell Darren C. Phillips Andrew J. Souers Lloyd T. Lam Kyle D. Holen Andrew B. Lassman Martin J. van den Bent Hao Xiong
Topics: Glioma Diagnosis and Treatment (21 papers)Cancer Treatment and Pharmacology (11 papers)Colorectal Cancer Treatments and Studies (7 papers)
Cited by: Genetics Oncology Hematology
Journals: Journal of Clinical Oncology Neurology Cancer
Partner nations: United States Netherlands Australia

In The Last Decade

Lisa Roberts-Rapp

34 papers receiving 631 citations

Peers

Countries citing papers authored by Lisa Roberts-Rapp

Since Specialization

Citations

This map shows the geographic impact of Lisa Roberts-Rapp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Roberts-Rapp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Roberts-Rapp more than expected).

Fields of papers citing papers by Lisa Roberts-Rapp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Roberts-Rapp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Roberts-Rapp. The network helps show where Lisa Roberts-Rapp may publish in the future.

Co-authorship network of co-authors of Lisa Roberts-Rapp

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Roberts-Rapp. A scholar is included among the top collaborators of Lisa Roberts-Rapp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Roberts-Rapp. Lisa Roberts-Rapp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genomic alterations in circulating tumor DNA (ctDNA) and response to telisotuzumab adizutecan (ABBV-400) treatment in patients (pts) with colorectal cancer (CRC). 2025 ·Journal of Clinical Oncology ·Michael Cecchini,Manish Sharma,Yasutoshi Kuboki,Ruth Perets,Jonathan Cohen,Judith Raimbourg,Takako Eguchi Nakajima,Marcia Cruz‐Correa,François Ghiringhelli,Kanwal Pratap Singh Raghav,Athanasios Vasilopoulos,(unknown),(unknown),(unknown),Zoe Hunter,(unknown),Lisa Roberts-Rapp,John H. Strickler	0
2	P3.13D.09 Prevalence and Prognostic Impact of SEZ6 Expression in a Real-World Cohort of Patients with Small-Cell Lung Cancer 2024 ·Journal of Thoracic Oncology ·Shui Wang,Aiping Luo,Nusrat Choudhury,L. Wang,Dongsheng Xu,Fang Jiang,Lisa Roberts-Rapp,(unknown),(unknown),Nandini Rudra-Ganguly,Peter Ansell,(unknown),(unknown)	0
3	1397P Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort 2023 ·Annals of Oncology ·Jair Bar,(unknown),(unknown),Shobhit Baijal,Weidong Zhao,Alexander Liede,Leon Raskin,Athanasios Vasilopoulos,Ming Li,Lisa Roberts-Rapp,Fang Jiang,Christine K. Ratajczak,Shun Lü,Peter Ansell,D. Ross Camidge	2
4	A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR 2020 ·Investigational New Drugs ·James M. Cleary,Emiliano Calvo,Víctor Moreno,Dejan Juric,Geoffrey I. Shapiro,(unknown),Beibei Hu,(unknown),(unknown),Lisa Roberts-Rapp,Peter Ansell,Hao Xiong,Christopher Ocampo,Anthony W. Tolcher	24
5	Comparison of Biomarker Assays for EGFR : Implications for Precision Medicine in Patients with Glioblastoma 2019 ·Clinical Cancer Research ·Andrew B. Lassman,Lisa Roberts-Rapp,И. А. Соколова,(unknown),Ekaterina Pestova,(unknown),(unknown),Zheng Zha,Xin Lü,Erica Gomez,Anahita Bhathena,David Maag,Priya Kumthekar,Hui Gan,Andrew M. Scott,(unknown),Kyle D. Holen,Peter Ansell,Martin J. van den Bent	25
6	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma 2019 ·Journal of Neuro-Oncology ·Andrew B. Lassman,Kenneth Aldape,Peter Ansell,Earle Bain,Walter J. Curran,Marica Eoli,Pim J. French,Manabu Kinoshita,Jim Looman,Minesh P. Mehta,Yoshihiro Muragaki,Yoshitaka Narita,Christopher Ocampo,Lisa Roberts-Rapp,(unknown),Michael A. Vogelbaum,Annemiek Walenkamp,Tony J. C. Wang,Peixin Zhang,Martin J. van den Bent	30
7	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized clinical trials in glioblastoma 2017 ·Annals of Oncology ·Martin J. van den Bent,Lisa Roberts-Rapp,Peter Ansell,(unknown),Jim Looman,Earle Bain,Clara B. Ocampo,Kyle D. Holen,Erica Gomez,Andrew B. Lassman	1
8	Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma 2017 ·Neuro-Oncology ·Hui Gan,David A. Reardon,Andrew B. Lassman,Ryan Merrell,Martin J. van den Bent,Nicholas Butowski,Zarnie Lwin,Helen Wheeler,Lisa Fichtel,Andrew M. Scott,Erica Gomez,(unknown),(unknown),Hao Xiong,Ho‐Jin Lee,Wijith Munasinghe,Lisa Roberts-Rapp,Peter Ansell,Kyle D. Holen,Priya Kumthekar	57
9	ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM) 2017 ·Neuro-Oncology ·Andrew B. Lassman,(unknown),Mahesh Mansukhani,Vundavalli V. Murty,Peter Ansell,Earle Bain,Kyle D. Holen,Lisa Roberts-Rapp,James Lee,Walter J. Curran,Minesh P. Mehta,Peter Canoll	8
10	HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues 2016 ·Molecular Cancer Therapeutics ·Xiaoyu Lin,Xiaoli Huang,Tamar Uziel,Paul Hessler,Daniel H. Albert,Lisa Roberts-Rapp,Keith F. McDaniel,Warren M. Kati,Yu Shen	45
11	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma 2016 ·Neuro-Oncology ·David A. Reardon,Andrew B. Lassman,Martin J. van den Bent,Priya Kumthekar,Ryan Merrell,Andrew M. Scott,Lisa Fichtel,Erik P. Sulman,Erica Gomez,(unknown),Ho‐Jin Lee,Wijith Munasinghe,Hao Xiong,(unknown),Lisa Roberts-Rapp,Peter Ansell,Kyle D. Holen,Hui Gan	86
12	Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM) 2016 ·Annals of Oncology ·Andrew B. Lassman,Martin J. van den Bent,Hui Gan,David A. Reardon,Priya Kumthekar,Nicholas Butowski,Zarnie Lwin,Tom Mikkelsen,Burt Nabors,Kyriakos P. Papadopoulos,Marta Peñas-Prado,John Simes,Helen Wheeler,Erica Gomez,(unknown),Lisa Roberts-Rapp,Hao Xiong,Earle Bain,Kyle D. Holen,Ryan Merrell	2
13	MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor 2015 ·Molecular Cancer Therapeutics ·Yu Xiao,Paul Nimmer,George S. Sheppard,Milan Bruncko,Paul Hessler,Xin Lü,Lisa Roberts-Rapp,William N. Pappano,Steven W. Elmore,Andrew J. Souers,Joel Johansson,Darren C. Phillips	89
14	Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) 2015 ·Blood Cancer Journal ·Darren C. Phillips,(unknown),Lloyd T. Lam,(unknown),Lisa Roberts-Rapp,Andrew J. Souers,(unknown)	94
15	ATNT-01ABT-414 MONO- OR COMBINATION THERAPY WITH TEMOZOLOMIDE (TMZ) RECHALLENGE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) AND AMPLIFIED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR): A PHASE I STUDY 2015 ·Neuro-Oncology ·Hui Gan,Priya Kumthekar,Andrew B. Lassman,Ryan Merrell,Martin J. van den Bent,Kyriakos P. Papadopoulos,Andrew M. Scott,Erica Gomez,(unknown),(unknown),Hao Xiong,Ho‐Jin Lee,Wijith Munasinghe,Lisa Roberts-Rapp,Peter Ansell,Kyle D. Holen,Rose Lai,David A. Reardon	2
16	28PD Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM) 2015 ·Annals of Oncology ·Lisa Roberts-Rapp,Peter Ansell,(unknown),(unknown),И. А. Соколова,Hui Gan,K. Papadopoulos,Andrew B. Lassman,Ryan Merrell,Priya Kumthekar,Andrew M. Scott,Erica Gomez,(unknown),Anahita Bhathena,Kyle D. Holen,Rose Lai,David A. Reardon,Martin J. van den Bent	2
17	Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies 2015 ·Investigational New Drugs ·Guillermo Garcia‐Manero,Raoul Tibes,Tapan M. Kadia,Hagop Kantarjian,Martha Arellano,(unknown),Hao Xiong,Qin Qin,Wijith Munasinghe,Lisa Roberts-Rapp,Peter Ansell,Daniel H. Albert,Brian Oliver,Mark D. McKee,Justin L. Ricker,H. Jean Khoury	20
18	2903 Identifying the correct patient (pt) population for ABT-414: Biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM) 2015 ·European Journal of Cancer ·Martin J. van den Bent,Lisa Roberts-Rapp,Peter Ansell,(unknown),Min Song,И. А. Соколова,Hui Gan,K. Papadopoulos,Andrew B. Lassman,Ryan Merrell,Priya Kumthekar,(unknown),Erica Gomez,(unknown),Anahita Bhathena,Kyle D. Holen,Renchun Lai,Dean B. Reardon	2
19	ATNT-02DETERMINANTS OF RESPONSES AND RESISTANCE TO ABT-414: RESULTS OF NEXT-GENERATION SEQUENCING 2015 ·Neuro-Oncology ·Andrew M. Scott,Lisa Roberts-Rapp,Hui Gan,Xin Lü,Andrew B. Lassman,Martin J. van den Bent,Kyriakos P. Papadopoulos,Ryan Merrell,Priya Kumthekar,David A. Reardon,И. А. Соколова,(unknown),(unknown),Erica Gomez,(unknown),Anahita Bhathena,Kyle D. Holen,Rose Lai,Peter Ansell	2
20	Multiplex Analysis of Anti-Apoptotic BCL2 Family and Caspase 3 Activation by Microbead Arrays 2014 ·Assay and Drug Development Technologies ·Lloyd T. Lam,Lisa Roberts-Rapp	5

About Lisa Roberts-Rapp

Lisa Roberts-Rapp is a scholar working on Genetics, Oncology and Cancer Research, having authored 36 papers that have together received 634 indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (21 papers), Cancer Treatment and Pharmacology (11 papers) and Colorectal Cancer Treatments and Studies (7 papers). The work is most often cited by research in Genetics (248 citations), Oncology (272 citations) and Hematology (98 citations). Lisa Roberts-Rapp has collaborated with scholars based in United States, Netherlands and Australia. Frequent co-authors include Peter Ansell, Darren C. Phillips, Andrew J. Souers, Lloyd T. Lam, Kyle D. Holen, Andrew B. Lassman, Martin J. van den Bent, Hao Xiong, Erica Gomez and Priya Kumthekar. Their work appears in journals such as Journal of Clinical Oncology, Neurology and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact